Victoza (liraglutide, diabetes label)
Daily liraglutide for type 2 diabetes — the same molecule as Saxenda at lower doses. No cash price published.
- Medication
- brand
- Form
- injection
Novo publishes no self-pay price for Victoza; its product page directs to a coverage checker rather than a figure. Generic liraglutide exists and is priced separately by the pharmacies dispensing it.
How much does Victoza (liraglutide, diabetes label) cost a month?
halfrx records no verified price for Victoza (liraglutide, diabetes label): nothing it publishes states an all-in monthly figure, so this medication carries no price here rather than a guess. What it costs once titrated is not published, which is a fact about the seller rather than a gap in the data. Daily liraglutide for type 2 diabetes — the same molecule as Saxenda at lower doses. No cash price published. No FTC action, state action, BBB F grade or FDA warning letter is recorded against it. It scores 3.1 out of 10 on a published formula that is arithmetic over these stored fields, not an editor's opinion. Novo publishes no self-pay price for Victoza; its product page directs to a coverage checker rather than a figure. The medication is the branded, FDA-approved product rather than a compounded copy. The page rests on 1 cited source, at least one of them a manufacturer, regulator or journal.
No clinician has reviewed this page. Every clinical statement on it is drawn from the FDA label or the trial cited beside it, and every price carries the date it was verified — but that is sourcing, not medical review, and the two are not the same thing. What we do and do not check · Who checked the price
Pros
Cons
- −Novo publishes no cash price and its page routes to a coverage checker instead of a figure.[1]
- −Daily injection rather than weekly, and at doses below the 3 mg the weight-loss trials used.[1]
- −Weight loss is off-label here; the percentages quoted for liraglutide come from Saxenda's trials at a higher dose.[1]
How this score is built
- 0.0/3.5Evidence — no pivotal trial for this product
- 3.0/3Approval — FDA approved for type 2 diabetes and cardiovascular risk reduction. Weight loss is off-label use.
- 0.0/2.5Cost — no verified price
- 0.1/1Caveats — −0.9 for off_label_for_weight, weaker_molecule
Clinical evidence
FDA approved for type 2 diabetes and cardiovascular risk reduction. Weight loss is off-label use.
LEAD and LEADER trials in type 2 diabetes. The weight-loss figures quoted for liraglutide come from the SCALE trials, which were run at the higher 3 mg dose sold as Saxenda rather than at Victoza's doses.
What Victoza costs without insurance, and every route to the same drug →
Sources
- [1] Victoza product page, NovoCareprimary
Information only, not medical advice. Prices and terms change; the date above is when we last verified this one.